BioSpace News Archive

Day One Biopharmaceuticals aims to provide a business solution to a moral problem: the inequity in pediatric oncology drug development.

The Heart Failure Society of America (HFSA) is pleased to announce the Late Breaking Clinical Trials coming to its Annual Scientific Meeting (ASM), which will take place September 30 – October 3, 2022, at the Gaylord National Harbor, just outside of Washington, DC.

On August 30, 2022, Broncus (02216.HK), the leader in the field of interventional pulmonology in China, reported its interim result for the six months ended June 30, 2022 (the “Reporting Period”).

Harbour BioMed (“HBM”, or the “Company"; HKEX: 02142), today announced its interim results for the six months ended June 30, 2022.

Today, the U.S. Food and Drug Administration amended the emergency use authorizations (EUAs) of the Moderna COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine to authorize bivalent formulations of the vaccines for use as a single booster dose at least two months following primary or booster vaccination.

Transgene, a biotech company that designs and develops virus-based immunotherapeutics against cancer, announces that Management will participate in the upcoming investor events.

Positive preclinical data in Science Translational Medicine, published , outlines the mechanisms of the three proteins, which have been shown to restore heart function following a heart attack in mice.

Calgary, Alberta--(Newsfile Corp. - August 31, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) received numerous enquiries about the press release of August 30, 2022. This press release details the results in a table format and clarifies a misprint.

LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that David Roberts, President, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14, 2022, at 4:40 PM ET at the Sheraton New York Hotel, New York.

MorphoSys AG announced that Malte Peters, M.D., the company’s Chief Research and Development Officer and Management Board member, has decided to retire at the end of 2022.